0001193125-14-343209.txt : 201409160001193125-14-343209.hdr.sgml : 2014091620140916172404ACCESSION NUMBER:0001193125-14-343209CONFORMED SUBMISSION TYPE:425PUBLIC DOCUMENT COUNT:14FILED AS OF DATE:20140916DATE AS OF CHANGE:20140916

SUBJECT COMPANY:

COMPANY DATA:COMPANY CONFORMED NAME:AUXILIUM PHARMACEUTICALS INCCENTRAL INDEX KEY:0001182129STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS NUMBER:233016883STATE OF INCORPORATION:DEFISCAL YEAR END:1231

FILING VALUES:FORM TYPE:425SEC ACT:1934 ActSEC FILE NUMBER:000-50855FILM NUMBER:141106190

BUSINESS ADDRESS:STREET 1:640 LEE ROADCITY:CHESTERBROOKSTATE:PAZIP:19087BUSINESS PHONE:484 321 5900

MAIL ADDRESS:STREET 1:640 LEE ROADCITY:CHESTERBROOKSTATE:PAZIP:19087

FILED BY:

COMPANY DATA:COMPANY CONFORMED NAME:Endo International plcCENTRAL INDEX KEY:0001593034STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS NUMBER:000000000STATE OF INCORPORATION:L2FISCAL YEAR END:1231

FILING VALUES:FORM TYPE:425

BUSINESS ADDRESS:STREET 1:25-28 NORTH WALL QUAYCITY:DUBLINSTATE:L2ZIP:1BUSINESS PHONE:416-216-0000

MAIL ADDRESS:STREET 1:25-28 NORTH WALL QUAYCITY:DUBLINSTATE:L2ZIP:1

FORMER COMPANY:FORMER CONFORMED NAME:Endo International LtdDATE OF NAME CHANGE:20131203

FORMER COMPANY:FORMER CONFORMED NAME:Sportwell LtdDATE OF NAME CHANGE:20131126

4251d790123d425.htm425

425

Filed by Endo International plc (Commission File No.001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the SecuritiesExchange Act of 1934

Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 000-50855)

The following presentation is to be used during Endos investor presentation on September16, 2014:

Endo Auxilium: Compelling Business Combination

Endo Presents a Value Creating Proposal

September16, 2014

2014 EndoPharmaceuticals Inc. All rights reserved.

Additional Information

ADDITIONAL INFORMATION

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities.This communication relates to a proposal which Endo International plc (Endo) has made for a business combination transaction with Auxilium Pharmaceuticals, Inc. (Auxilium). In furtherance of this proposal and subject tofuture developments, Endo (and, if a negotiated transaction is agreed, Auxilium) may file one or more registration statements, prospectuses, proxy statements or other documents with the U.S. Securities and Exchange Commission (SEC). Thiscommunication is not a substitute for any registration statement, prospectus, proxy statement or other document Endo and/or Auxilium may file with the SEC in connection with the proposed transaction. INVESTORS AND

SECURITY HOLDERS OF ENDO AND AUXILIUM ARE URGED TO READ THE REGISTRATION STATEMENT, PROSPECTUS, PROXY STATEMENT AND OTHERDOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any definitive proxy statement (if and when available) will be mailed tostockholders of Auxilium. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by Endo through the web site maintained by the SEC at http://www.sec.gov.

CERTAIN INFORMATION REGARDING PARTICIPANTS

Endo and certain of its directors and executive officers may be deemed to be participants in any solicitation with respectto the proposed transaction under the rules of the SEC. Security holders may obtain information regarding the names and interests of Endos directors and executive officers in Endo Health Solutions Inc.s (EHSI) Annual Reporton Form 10-K for the year ended December31, 2013, which was filed with the SEC on March3, 2014, and Endos proxy statement for the 2014 Annual General Meeting of Shareholders, which was filed with the SEC on April29, 2014.These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants in the proxy solicitation and a description of their direct and indirect interests, by securityholdings or otherwise, will also be included in any proxy statement and other relevant materials to be filed with the SEC if and when they become available.

All trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of their respective owners. Xiaflex, Testim, Testopel,Stendra, ErecAid and Striant and the related logos are the property of Auxilium. All other trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of Endo

2

2014 Endo Pharmaceuticals Inc. All rights reserved.

Forward-Looking Statements

This communication maycontain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. These forward-looking statements include, but are not limited to, statements regarding Endosoffer to acquire Auxilium, its financing of the proposed transaction, its expected future performance (including expected results of operations and financial guidance), and the combined companys future financial condition, operating results,strategy and plans. Statements including words such as believes, expects, anticipates, intends, estimates, plan, will, may, look forward,intend, guidance, future or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-lookingstatements involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forwardlooking statements or information in this communication. Investors should note that many factors, as more fully described in the documents filed by Endo with the SEC and with securities regulators in Canada on the System for Electronic DocumentAnalysis and Retrieval (SEDAR), including under the caption Risk Factors in EHSIs Form 10-K and Endos Form 10-Q and Form 8-K filings, as applicable, and as otherwise enumerated herein or therein, could affectEndos future financial results and could cause Endos actual results to differ materially from those expressed in forward-looking statements contained in this communication. Important factors that, individually or in the aggregate, couldcause our actual results to differ materially from expected and historical results include, but are not limited to: the ultimate outcome of any possible transaction between Endo and Auxilium, including the possibilities that Endo will notpursue a transaction with Auxilium and that Auxilium will reject a transaction with Endo; if a transaction between Endo and Auxilium were to occur, the ultimate outcome and results of integrating the operations of Endo and Auxilium, theultimate outcome of Endos operating strategy applied to Auxilium and the ultimate ability to realize synergies; the effects of the business combination of Endo and Auxilium, including the combined companys future financialcondition, operating results, strategy and plans; if a transaction between Endo and Auxilium were to occur, our ability to achieve significant upside potential for shareholders by accelerating the growth of Xiaflex, Testim and otherproducts of the resultant combined company; our ability to sustain and grow revenues and cash flow from operations in our markets and to maintain and grow our customer base, the need for innovation and the related capital expenditures and theunpredictable economic conditions in the United States and other markets; the impact of competition from other market participants; the development and commercialization of new products; the effects of governmental regulation onour business or potential business combination transaction; the availability and access, in general, of funds to meet our debt obligations prior to or when they become due and to fund our operations and necessary capital expenditures, eitherthrough (i)cash on hand, (ii)free cash flow, or (iii)access to the capital or credit markets; our ability to comply with all covenants in our indentures and credit facilities, any violation of which, if not cured in a timelymanner, could trigger a default of our other obligations under cross-default provisions; and the risks and uncertainties detailed by Auxilium with respect to its business as described in its reports and documents filed with the SEC.

All forward-looking statements attributable to us or any person acting on our behalf are expressly qualifiedin their entirely by this cautionary statement. These forward-looking statements speak only as of the date hereof. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, futuredevelopments or otherwise, except as may be required under applicable securities law.

3

2014 Endo Pharmaceuticals Inc. All rights reserved.

Proposed Transaction Overview

Proposed Price:$28.10 per share in cash and stock

Transaction Value: $2.2 billion

Premium:

25% to Auxiliums closing price on September12, 2014 42% to Auxiliums average closing price for previous 30 days

Consideration: Approximately equal mix of cash and Endo stock

Financing: Endo intends to fund transaction through combination of existing cash on hand and debt financing

4

2014 Endo Pharmaceuticals Inc. All rights reserved.

Endos Proposal is Value Creating for Auxilium Shareholders

Endos proposal provides Auxilium shareholders:

Substantial premium and immediate cash value

Opportunity to participate in significant upside potential of a leading global specialty healthcare company

The combination of Endo and Auxilium would:

Create opportunity to maximize value of Auxiliums products by leveraging strengths of combined company

Enhance the long term organic growth for combined branded pharmaceutical business

Expand R&D capabilities and development programs

Generate significant synergy opportunities in addition to Auxiliums announced restructuring

Create company with enhanced financial flexibility, proven M&A platform and established corporate structure

5

2014 Endo Pharmaceuticals Inc. All rightsreserved.

Substantial Value for Auxilium Shareholders

OfferPrice Premium

Endo offer price of $28.10 per share, mix of cash and stock

44% 42%

35%

28%

25% 24%

Premium to 9/12/14 Close Premium to 30 Day VWAP Premium to 60 Day VWAP Premium to 180 Day VWAP Premium to 360 Day VWAP Premium to 720 Day VWAP

Endos proposal represents substantial premium for Auxilium shareholders

6

2014 Endo Pharmaceuticals Inc. All rights reserved.

Demonstrated Record of Value Enhancing Transactions

Paladin Labs for cash and stock in November 2013

Expand global footprint into Canada and emerging markets

Establish Irish domicile for advantaged corporate platform

Boca Pharmacal in August 2013 and DAVA Pharmaceuticals in June 2014

Add significant near-term EBITDA and cash flow from operations to support future M&A

Expand generics R&D platform supporting long term organic growth

Grupo Farmaceutico Somar in April 2014

Addplatform for organic growth in emerging markets with established commercial footprint, manufacturing capabilities and pipeline of products

Sumavel DosePro in April 2014

Leveragecommercial capabilities and Ireland-based platform

7

2014 Endo Pharmaceuticals Inc. All rights reserved.

Combination Aligns with Endos Strategic Direction

Endo executing strategic plan to enhance shareholder value:

Meeting or exceeding financial targets

Maximizingthe growth potential of core businesses

Continued investment in de-risked R&D

Lean and efficient operating model

Pursuing accretive value creating M&A that delivers compelling financial returns and future organic growth options

Value creating combination

Addition of Auxiliums Xiaflex and other products complements Endos branded pharmaceuticals portfolio

Opportunity for Xiaflex in potential new indications supports long term organic growth

Combined companies will have broad range of therapeutic options in mens health

Enhanced operating efficiencies

Combination will enhance value for both Auxilium and Endo shareholders

8

2014 Endo Pharmaceuticals Inc. All rightsreserved.

Compelling Strategic Rationale

Auxiliums 12FDA-approved products in urology, orthopedics, and other areas are natural complements to mens health and pain products in Endos branded pharmaceuticals portfolio

Endo expects to optimize Auxiliums portfolio of products by leveraging scale, competencies and resources

Drive increased adoption and continued strong performance for Auxiliums Xiaflex

Support development of Xiaflex for potential new indications

Optimize Auxiliums broader portfolio

Combined company will be well positioned to drive organic growth for branded pharmaceuticals business

Highly complementary portfolio to maximize the value of Auxiliums commercial products

9

2014 Endo Pharmaceuticals Inc. All rights reserved.

Select Highlights of Complementary Product Portfolio

Mens Health / Urology Orthopedics / Pain Other Specialty

10

2014 Endo Pharmaceuticals Inc. Allrights reserved.

Strong Pro Forma Financial Profile

Enhanced nearand long term revenue growth profile

Significant synergy opportunity leads to improved operating margins

Robust financial returns that are well in excess of combined cost of capital

Immediate accretion and enhanced cash flows provides balance sheet flexibility and rapid de-levering

Deal structure enables continued execution of Endos strategy

Synergies driven by complementary nature of companies product portfolios and geographic locations

Synergies would be in addition to $75M reduction in annual operating expenses announced by Auxilium on September9,2014, as part of Auxiliums recently announced corporate restructuring initiative

11

2014 Endo Pharmaceuticals Inc. All rights reserved.

Endo Prepared to Engage

Endos proposalprovides Auxilium shareholders:

Substantial premium and immediate cash value

Opportunity to participate in significant upside potential of a leading global specialty healthcare company

The combination of Endo and Auxilium would:

Create opportunity to maximize value of Auxiliums products by leveraging strengths of combined company

Enhance the long term organic growth for combined branded pharmaceutical business

Expand R&D capabilities and development programs

Generate significant synergy opportunities in addition to Auxiliums announced restructuring

Create company with enhanced financial flexibility, proven M&A platform and established corporate structure

Proposal subject to the completion of due diligence review and negotiation of mutually acceptable definitive transaction agreements containing customary closing conditions

12

2014 Endo Pharmaceuticals Inc. All rights reserved.

EndoAuxilium: Compelling Business Combination

Endo Presents a Value Creating Proposal

September16, 2014

2014 EndoPharmaceuticals Inc. All rights reserved.

GRAPHIC2g79012330.jpgGRAPHIC

begin 644 g79012330.jpgM_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%DM;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#M`P,#`P,#`P,#_\``$0@"E`-P`P$1``(1`0,1`?_$`,\``0`#`0`#`0$!````M```````&!P@%`P0)`@$*`0$!``$%`0$!`````````````0`\!X#P'@/M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!MX#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'M@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`M\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#PM'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>M`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#MP'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`M>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!XM#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!MX#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'M@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`M\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#PM'@/`>!Z,E)QL,P=2DQ(,8J,8I97>R,D[08L&B&N?>O5LW7C5IK:^VTXB(B9F9_"(ZRT>1R./Q--N3RME-7'I&;6O:*UK'UFTMS$1'XS+]L)!A*LFLE%O6DE'/D4W+)^PO7"35HW2QZ8RHNX7W3113QZ_MUSMG&/,14I?9>->N)M>?A$1F9_*(>J]V[3Q]5M_(O6FFL9FUIBM8CZS,XB(_M-QQ\P$BS1=06*!TE3;;8UNLUS^68AM.#W7M?=(M;MO)X_(K7XSJV4V8_/T3./XNXNX0:HJMN72R+9NCIE19==31%%)/7'KMNJJIMKHGIKC_`%SG.,8\T*UM:8K6)FT_*&]OM>FND[-DQ77$9F9G$1'XS/P$TC5)HD@(C295U;P^\I,1T?I++[ZZ;Z(MQNSMPEA\KOJIKG&J7OSG&V/Z?U\UM7%Y6^;1IU[+S2,V]-9GTQ^.(Z?Q;/D]MS[;PXUVY?(T:J[IQK]>RM?7/TIZICU3U^$9=35^QW=J1^CQIN_12U769:N$=MG:2._M]JRC;&^5M$MO?CTVSKC&?7'FG.N\4^Y-9]$S\#A2].ZQI2D`*P-M;DR%8YF-QI6#^1D#2C1]F:77UV_(&%'V"Q*2]@?6V#E]36+>0I($UU,;!H^MB:,@Y4Y907,10ZT:R,M1+GM>"IS$P,ZV0=;Q#V4P@KNEJOHFKNAIIL(9RB>7>R@:HE&YK27^:B"5Y1XM+J$WAB[3-K5NM=IG1]7V&+ME4)(B91).XUW5RXDL)MJ-7`1:'X&Z9-J.B!>TZ^L-Q-5]Q+]@8Q5,$YMA.$4%+X(NGY$KXZ2;,A6W)ZM&8%@E5+>/R-.]I64:"226K9.03W3QML.C7(,$]'U3UW8EVM^?;(N!&;H?]O8M4T7.JQCRW2Q!6IJOAQVK>7SW_-+:/F0FRR,:=J2(Z5PD,Q@B3#Z52EDDGVJ#MH/IK?(S#'M%6H'E54R-RCIE79,.$M-L).#B9>P(2?A7,;-!3"7FB$9@8^4EXM]TJW176E6"*:VVNV'2/IA74CXF-.9K^.G_-YG=U'WQ>E2\Z]PH3])CU^D50DM'7HCSV7\MF8+/2]DS`U8T>+&L,(=,S$4\CW$A,OS/C[5%%BD4C4-8HL=1^T@LQ)V([\$U/V8([Y?6`S,K3)="M"@,RMK,2OJ+6/)",]MG66T>7HK0^I.[B,CS0AOT='_6Y'MQHN\@^@H[6.JKLB>Z3Z)C677\]//[3%4-XHR/4-S*.(F360FX*'S^O\`UC;9MQM'^!K5/D_LAWUS>)0$K*N[`,9"WE;%*(.[1V`0M5B1E?;;OYPJE0O8F:K$C31=KHV89V69K/E]?Q,C#@`/?-N2+(9*K^"FEM,#S+M_K2BE%JY(QT^B2JN^C*QI$AL*0@S*^JD$GD87Q[*7([AY_&M"J8(88J@G,%O&UK6Y02!$F.PY2^E5TU9G1OJX9-D'C99088/9`+8TSTY+V3#@K=W;>]6PR0D680?MF!J3+)#5_#3"V6;25A5$'7^QA;VZ#'7"JY'[.VXY?L!SL5T?(LCN-)J$KZYHMT=/4"Z6KVPNA$X-R.L`Z'CQ!OO:(:#QA;$2!3.?-"Z1D8\W\P:PHQ$HQ"O[7:RRJ"4K6?>2S=BMNT:HQ[%/=LY=.'2#788>KQ?]D8?V>;K#0I6\^/CTY5ZES5V9:S&I(QE`/4FBMQYLPL5%I"1S.L;&E6Q#'2C*"P\E\.8U9?;#K"S)T@F,.*C]E*?YC8F>4&4MJM)-"'IH%IFW$CV2PSCINO-$-)V6E:7MD[D)A)H,#MB4HV0>!L+'++2DM*SD8P9L&3C;XU'.[=#8BHN9NZ+KZNG:W=PRMM$5('(NW]N?`SH(?8/1EA'1L,5]*0AZ)!1MQ5`4ZMH1LRHY&MGV;2KTML7,\Q('AW&MI*.#8T/GB6RM:]&H\MINN[AK^SI^R@2)!+':V:[?3.,%PC[+NOGK)1P,,&9T,#!`8OUW:+!!F+PTU*,I&>&`$)C;--],S).*M996>AVK%!PC[\N$$_39PCK_JLGC8,SM#???$Y=;=9OVIE4#)I:U`#UKUET"2%-=#T>31Q4?N:_951#3ZI+UI1!K.[4BKL$N8D]C9PK`585L]=3,/N-NWLDNHMD\44_%\"[9WZW;,BJAY\C@.8"FUE4AUKTUTA/PXM8!M1T-9K3H(FZ)5:_);`M8#$A>.'XH.W2U4U?*PDD@NNT=,MO1!QH[3$*GL+ZL[HS7YS5=00/-D6%7%S=MSM34PWLT\M0_EJ"F:#MJS+15_P`7D4I6[J:LN#*GEFK+,W,CN,N(299:/=6SME+9-F@,KP_[&N@P"XUKP`F7.-IRCFVNXY;->V[+FI.>BBEM-Q-=M&ZZ=@A>U.?KI*._6Y:2L/-.T$Y%OMC_=&75EN1.MAE>^HZIR"H(4?LKL>#Z5M8RD693H">E`#/UDP$3^JER3-*6-BF9P>+H)E(1A%"Z3;N5BPH>>"!QL$S@X$.VMIE.9H.6!;+'/KWULJUW4@9-;7J6;XI$*B&)N%I^"P$/(PPA"1W4NLH+O7LR.M*C35"=O!H!DW(H.S6],[R\45QCR5>,Y1^@HI#J9:M;[.!EZ[+@FZ!5U1Q33\*!TW:4#9!L8659KCIFW;FE$!FUKK$+,NL(F($^I5KM!W]"V]$B2:ZJ3[`@L-E/Q/XQSC.BJBPF4U^Q/CGJ'K&2T(Y\2M[LC9J-F$"S=QS=PGA!IHAAMIIAIMNAL'ZZ*X8YZZEFW,_;,.;*/IBM)JFC+0M(M&Q*V9V-5$VZ>22E?6*T!"2`2,1F.FI!P]9(/,*?BKN7&-,X2=.4E@E$)RAM5PO1$U2$(WB%6.Z66GNQLYPGAQOLKMDB&;XK5.K)0DOV?@8@9]NWZRJ@LOG"YN?(M&0(D]^B+&J,MN"S;0,3RV+*G8:N#0#>[,&)H3D[@G9R,/7(;M!CGM>:LXG=;M\C=%?;=UAR7+:AU1E764]JET:"K.::TJ5JFU>P*VZJ8M%$NP.45VTD7@REOIM"3/ZFNI$":_6-R,UR;I;"IV]BC@M!O*J]QN2N"T9$3#JVZ.G(@HN`*K47>%:L'7L(5D\(B_]L4@V6:JX]C=1-#1)M%,N5YSO)]'DA*7%TN+O7$Z2@MWD/KOEI(L'Z_Y>JZ^V%L!S!^OCMR`@\16PC.'H/'$J,`4$46"CT=%J/%TOF?M(UGH\MRXPU;_&3*O7_`-MMM,J)*Z*;;;9"&L/KBYCCATBA4MV5J.YF)HDR83-BC26(W`R0?T,19G,/%GC1N\^3\5=PXQIG"3ITDML1^''"O.[FW4KD5@S#]Q@W&+4>A6ME'NE0S5PA8W$"`I8FX4YQ*F3IN\&2.,D=A>A1:&*!P^-!PO$$N95C=Q2DV%DT1-M988*!M#:Q9C39^V4T6DFSU1N^RY;;;);!U77&=)R\7)1Y6D>G3R;H&R>9I\F.;-.BHMNGJCMJ:3GSF%EB.5G%Y)Q(2,BCI^.]QOHYCD--&[39!#31/4N7I/N*J@V)#PMN&9RY:XGK($Z[%"MW65UV2$(O/\`%;6,B@HF2CX8@1CFY@P&H9M#N'^$O?(1M"6&KK"R?KC(RES#E*C(JC07G*-$%F525S.5R2BHZC/S_`.4VGZLL:"MD3EGTM\I)*3LL]Q8(XWD7N[IPKF05RIAQ\FJJFNQ$,E^$>7R%\4/2&NMIW0U`\!X#P(W'F(E+9](PG@'^W^F4VLNP65US_X;(Z+Y5TS_`.6PD>-6E+@0M)6&/L4M_P`OXFD*9O(I8BC$$,2#C">J+C3">'*V-?3"JGN#OQU;UW#N()Y$@07%NQ=VM6/QEU'"T&RP2[9BDK$.S241*]0UBM=#:/Q$M[;5!!=2RD(S#)6,U8(G&T7DF3::QJ^[;&F'.-E83=I^1N]QNX7:[(^_.R>=/`@P7S7SK7#M-"/KZA*8!F+6TF'>K!UKC"[/5RKMJCMIA3;&0\[NF^?\6_&VV^J^HL7R\CW2,18[H-#\6L[C8J.2B'F(XJ5C_P"5MN&T9$2.C139-?.$&KC".W(>Z3412)H?#=JF%/5@4V6#(N.%>MM*BYV;GH!U5%SPC'#E`T99=,UZI"R(/&4Q6`!*D8D_LR1BG,:P09#ZT9_A^-MBG.V'Z4?%L8M5#X$MLK;>!Y^B^7.W0KF`CB-V81T*K&+PV[/:+CRY^O*MT/9\2,DMNZTQJOOMOD.].MTY4917&M.DE75W/5)I&1D*G5\P%CDC7J,/"*-E86+0#7%5E-M@D(K3%/@T:(PP555QLNO+.D`L/BAV&@2*2KJUH6Z6V=KN-G*#O;;?*NO@1\)YHYRK5ONTKR@Z8!6NY/&&VSM80K`*'$/YC!IO480IU2B(1IIH0PB,DXT9O,8PX:Z.%-4MM,;[8R'=?T?2\J[M%G\G4=9R#X&,IZQ0MX\!!=PZ$;`*7C^1)S@:RL&7$.+4H/ZD,-:DKKA>#-8`B8M4YI^V@MX5+751=6HJ#L#J>]Z>N7N)FM)VR5S_\`&./;[/J@-W.)S>]QCL:=CM'FE-#?(M):?5#=CNIJ@E!C]/6]W=*MU$6V%O$C$V%JUB.+X-Y.)1BYYVR3V'7SU?.F4&S9IE1EH'TL^LZR[?LR(M64M/;[@+R$-(RJW0TEB8ER4]"#F4A"1>T8@PF'7-?,T;$-)-RC%KLQK6*?/QMUAMZ@X#.S?L9EEGE(1-U*W1=Y34MT#-H]&0MB#195S@@7:ZUL*1;20%67ZEZJBLFLILBOKHIM%PN&\[HZ^IB=M/*@5N>PY&H!GLPJ$59M_NNXD8J:4C70PV!8F-1FMM$/RI#RQ"DMOVQ"C,1#?8&6%B\:+"Z"]WM(EB2#293NI/8.T,M[1&X]2PTQ!ALENMASOK)!S*"L[K5EV56YA>,":56,W=3/UZ-^HR\5KI3>;QTM:[JRV5PVHC"(D8*395O3YF1\TCIO8`WRMPA`38T2LZKT))#:(M02@227L*4>%";AREB/QIC3\-F,_`QT_%ZO3*_65[95Y$[7GHR%BA(9)W5;6Z$?7Q$5V(2U[$/W\M&,V2+DLK_`(7CMU3\C$?-1S^Y[BK:GQ"Q8KHN!L.M!$0M2TABRYF5?-1SV_-T6348IMA+[W>$/`>`\".;EPVEFN$]E]U$]=!Y-5$]\:YTWTVQOK[M,Z[:[8WU_]M[7.,Y]VO_GCP/WX%/67>M>5.358%E;DA1B@D/AI4NB6*MDE++LVN7LFW1TWVWWSC4+=\!X$8-@H2L@/**_/1V)+@DV@)86+1>>9I2$*0#MLZQ6C9>'E&2^NR3EC(,7&Z2FF)O:WD5UIG363[U%1)=+F$G>H*M$62YR_E$[Q(QR*1(IUY1$J0)%!M="1]POXN+^?%5Q=OJ,D>0'0JZJMPCR%L#BL2[A[#B5VQ6*ZCW4?+MR*,YZ"74X'C)UBDJ9)1)TB4IC@0_,BL`*)M'*`I"AX3',/84H76LVFF,+!5T%BMAG*6YL,0Q];V:ZYRE;MD8E5J(PO4DZ3ZG]M+]0DA98365CDW5DJ`,E;!5+/5[#2K2P8R8@6-EOJ&SQ\K`I%Q,X>M3-\CM0"`;?2HOG_R&^)]=ER8^1GYM!Q8M@$&K87[@$.!A0`IP-E]T_X^MR^S:K8[!AQ?'A80#W8HR+5A/ECYXU7QSV;0:*-OBUHT'M78)=F6):-VK))9Y*NE%``7:9$DQ$B@A*>V?]&0X>@G[-^^FR&TF*HBQRB!(QMR)F=WOR))(6-0/TDL?(K6/Q4?E[)V_>L'XY&EQL&/N>RE;)SQ+*TV02@7$BAMBM[:A55Y)Y"?^*BHOVL:V+=)6^7O4=HRI[-FH%M5[0[=6&NVV"8K*KQK&T5&M;>0,Q]6*+G5D_+[?*'6MM3/O>O;/3I@YN-C/&N5!+`X:*>-9&`E1E5$*CT)04*@BFF0IA*7M`>W4-U[HL>9M8MIC;+;RX;C6JM9'!WI5HWB'.*B1"]H/S=4?\`0Q\6LWTLM34\T/7-[C?._9>V96,Z:#.T^!%#,2O&26+C[B*`>5TL;W`]/S%_5TP:WNM&WM#U@SUNKCN#AMB]125OH[]V=H="Q5@MS'MZ/SOQ-P/-OPO_`%JOQ1US=Z#MWM[_2ME876=Y%_(_)[FV,Z]6?J'[A_)J.B'RC)1PYBK7,/EZZ](=HZMGM6MK#/N=?@OQN9:F-*VJ)ZK.DBP5JOR+_`%=J/0NR]=2]I,=F1M%.MU8>+AJPT?I'0+FQN`;6/?\`.72.P=QZWK\WJ2QR=JT6MYQMGC0R.(TR'QRP:`N?"EU:ZEB%)4*67ER&/&U!WCUBM==ZCD>G*\:$U\PV5M4-@[?N>T)NIJG6CZ0^&60IFOHVOR;Y_87LS(B!0?'(@BFF0IC%*`CD@TQZYTM0Y6ZBVN/LMHV+)#C18Z2#[I1Q]V9G4!`H_R`DFY`)\5!NWK\@?-BZWJ&1UG/MZ]UN/9P9>QRG^>^6;[M0N51B8&&Z56`-2;&J1`[UGX7**6"=0(4L3IKI*[QW(@M>+^BV]WRS925\IY9\RG%UM:&C))1#:S%5)\2HT&LRIW.V79MD[2[S3LV)C8E5F+6S+36E89O4J'4P0`$Z>MT^,D;@70V.3M_,S3U'ROVM0Y;3V]8N;%9G1F;&!K[R1"E.1)"5L/JBR4)DC,C^`R#V,W_`'#BVZ]W^2;5Z7[TP=LR[Z38BV(MM>?DM6Y1]58HX#J&M!'4`2#+8[B[9B[Q@\%VG-Z_J>1F45V!6*,4?&J5U#+XCJ4E3IXZ$RC5%%O--=["!%XY8V$).CL9-L[7Z"'/E.HG5[DQ;JH/>ZPTI3;78WW-)Z)M+H*1VHYOR_G_`&I[G['SC@+`%M6T8ZDRY:O.;M:^\6^&:KCC75/'%J]I=[=7U=:[J)Q]/W+35P46#K($]1DU7[DFU6[DHOZ*LZJTV(UU.M,.FI@2"#TE5;H24O+W38-N[N[[FS/&GV7:=PW._;QMXW#GYAKX.C>:V(61QXJQ$VEVW:/VN3EM`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1M`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1+,VG'^2Y`KOLM[4U$>P0@E?+2R+V;&`M1'_F09S?21'5U/J9$9H5_B29#$'>'L/VK[[[!_5_NM9M-&?4@/HW@>GE8S'\?'R4TMJ.OB5!-;Z#U$$N3C7+N0[=]^RFQ7G%W?EG'ZC6[G`5(J0%*N.V[(?D;I37F[Z_7Y^K0FQH0\]%0=H(P).M,V/O[UBW.]"+>R#`0>ILPLW21%VKMHZ0.H@Y:N4%"G34(8Q#D,`@(M@.:4]CXWF.0%LC20010@C0@@Z@@]0NP0S0W$++BW>V2"1H7G,[4/#&EPEIV8,_-3-PECP%!U_3(]*7N=MVFDR(F7;0[!=RS;D:,O>40Q76!S.$N+(0DB^A,0E;-ZFTQ%P:7%OIDO&VMC0YFIKIF7FG+K2818>\6N9=&Y8V7?D%0ZK;(B/T+L0^N9"RS_P`'")M\FBZFMVJ[ZM!&R3YR#)+X+YO\`A)$3BBZ1-TZF,4NW\5MK&>^EB?)?6_JAC=VMZ,4::/J`*_%32HJUWLKRKMOW8P_.GLO&HBPME92+91DXU,_@G:0+,E5TA%$1`PE,0QK/-6:+VMA&QMCF8*I/&,>LG,0M=L2+I%!-[9G,@SRA-&!KF@GXMSG:FM/`'W2,-PGGKL[R7G4=KEM.YDF1:GI[RMMVF/_P!L>\?YS2F$60G%+DU'Z"@N1E-G*J\M-:Y$M:87U?(&BWZ$?+5V9CK3!76I6)H=VF=JZ;,+!7D0=-S@'FMS'*!BFZ#A%D+MGMU3=T;?A+[`W.C:X]WV!L&'VZX=NVUJX^(3[M*GVB4E9"T.)BTS9E"$U2XL]TOFY[^SL;RNS2[^EO]M^NX)WLZ*K!5;*9H$%*EKK9)!)XF[49I]P)'#J`@1=CGU>>3$HCMF/FZUJN:KM6Y9C:4[LV#+%6R)1E7^V9NESTH>)EXFXL+'7S5^5H4>K&'9.T3)=IP5%8IN@M3,JMC;'\Q&1E]U%1!UL7E!`T3ANDL+)M!-1TVZE.)^TH9%LI=@ZZJZ6BO6"M-1J/)W4FPJK95J3R.WO.M\G8JSZHGHRK[.TQMJ?.^:R):JYLK*1@[)5IN!>`Q>M'A"")2%52,4X9=Q3>DM2XM:YY\3J5,!04"U7R6D&^B/K%()KNQE9F)!4HF>V.U3'M8F@_LLTJ'FN/(3103,/:F0I0RAM;O]2FJBM\OZI#_P"^?U1_T,;]_P`PG.11M?K)X1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(FM$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBM81,(F$3")A$PB81,(F$3")A$PB81,(F$7PJH5),ZANO:0HF-T#J/0`ZCT#P\MWP\/EMR]MK&_NQNM[>X>WS;$]X_"QKA^-8NZS>%LCMO+RUA>/!\K&'\#G`^Y8_6/U&MN"E3.9*=Y6Z0;JD$0%)G?H*;5,)?;V)P3J3.IT^P`YGX.$M)0:?@K^)68G?63]-N`(8ZW)F!DNT>G;`U'8MGT/AM2/DF!A//NY0H`(B)>XGT1Z&$6JC$%R.$_,3[NWJ(?2#H/4/;X=1R(-14*)%%CWR+M_@FF/YQ6H?\`+:^"I'>'O"R*R*F3")A$PB81?F+W[]3>]4JT7NZV:/VCPO38M6*VV.=8INMH[83%(^'3_VJ;;\0Z]?'_P!0WCXX1^-$]KFN:^VA57\=K*];`GK8I(W.L+0T4HVCK#JNIQAVB3M0!7,9X4QM">)2F'PPB]QV$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%"O?%HY_\2?_`%HY*[YIM46BI`"P&YQ:;3+9*_N&]0'SRD`]*CXA0TT5DG8HKK*J."$7/W+"M914/-5$QA2'N$Z@&,)C"`]1]N90-:P?H!Z;O-E&_B``_$K"/XF4F_2-K^6Y[MC^$OK\BD"BA$S#VE(7QZ=H%[0^QT`O3VY3N9G.(!Z$:ZFI^57*GI)\:[\YTW4&_*GM/`=-37VK%WTM^/O&KD[RQYL;4VOJ"I27%M/1FLMG;+CM>K?&6]7A(QQ:5W&O631RSEFTFDI%TNLR"G51PH94W>)Q-US,=PM,[G\/Q?$8['W+VI"X>TT/A70^2Q/#\1ALER;*W-Y%&["6(>=MA%11P.R@]P)%/8K_`/H;%CI,XCX=K3H(P=`-2-%DOZ_'%7@UQ`TEQRA^-/'ZCZWMV#N2ZS4N\M6@_3H0`]@]H!T]@!VC[/L9WS]L+'T+0?B^)QK0K1^;W%]%F+CU))/4ER$C3)4M5:TR$`N-#X`46.\E;[8P>2'G;#GWM5UW8;='NGT)-0*5S/"1MSA(^*NLU&2CM-*/V9`Q8N'4&\:H+HN3+)"J!55^G3K%OB,+>V_Z+'P-S64@@D,18[TF/$%76M;9P28IR1ZH*-(].1C02*?I!1QJ!3=XM45,-=E[(8?$A=6F>9M;22WLVLQ)2]=L#:.3C=X0M-=6*`C&K,DA1T:G4990HMA)^8BY4`B@``I&$6=\;M+'ETEI%=:Q-8QQ(/F'.I7R\%D/JAR^L>J]=6"3?'E)&;IM?E'LFJ!15DM'+V/275>'$A"$$RXG[O`H!X^`!G/>46\=CRS)X^%C60PWTS0UHHUM'G1H\&@M]!X!9W'>K=6$%T[K)$UVO]H55:C'?Z#^D'[P>&8\*L8GU7'P_P#T']01_KAAM0])ZY^'#_:!_4_>PGI/7)8PQA`I2=QA'H!2D[A$1]@```(B(Y0=\Y/2?Y+J5MCS%Z@).G3V@(>("`^("`AU`0'+AH!-"H&-P%2KY:91\IK/AX>+F/^3I[$7&;M3@6AK):>;?Y"MHXW\R;_`%F_R%7KS/K9DPB81,(F$3")A$PB81,(F$3")A$PMB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3M")A$PBA'+]BR%N5X\:-#.EBMVI7+A%`7+@X@!$&X*G(*RQQ$``I>IA$?9A%)M%K=!)I3BB#E:14KJJ3>6:1+)[)OFSE8_8FV*T9(++N'`F]I$P,)>G4>F1H4JMH@LTY5?M6:$#+F;.8SXB,JN1JT8MU#E$R,OMCD$4SPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB814W'W&I2P](RSMP#\WL%-K+L%E2C\QD2+BJ0?L"`#D:$)55&4Q3`!BB!BCX@8H@("'S@(>`Y!%MSA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+'7D7_!-,?SBM0_Y;7R!4MKO#WA9%9%3)A$PB81,(F$5K]DH`X+$IG*!TS`_(H0>G0Q#E;%,7]PQ1Z9JO*M;2*^M?HER`ZRDCD;*"*TBH#!Z!WA+\`^$5+MX5O-@6^NN]DQ^UGIMAZ\B*+89FNV&6J&O)WJUN\Y0`>;]#+^:QS%T79*Z$DDDQ+MW.-3(XGJY_Y1).M3UZJB,?Z3!'$VD+0`T`4``%`!Y`=%9;UE_5#-Z6&F]6VFMI:O8[KW#MS84C"5C5CMW*M%#Z]H5=>V_;UZ5^!E/*$0J,$BW*4_:*":SH%%NMJ22@8Q5J>E/]/8L;^"7*2V>J[PJWE=A/":3?+;VW;H"MI6S4TQ+SK56M:XE8$D%=VL@]D&[U=>T,7X^\`U=(I&;J=43D[LRE[!'8S,:?MB&T$@]=1XJC)9BV?4DN:0/Y!_.MDVLJ#(:_US3*/*VB4N\E58!E#/K9,BH$GM/KMN[N>N@58_G69P0`9+0`:C^0JZ>9I9],(F$3")A$PBM81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"M)A$PB81?)SD3*8RARD*4ICF,B*D/RH5ER(D@DIMVU*`;M$*W`2@B,B=!O%`!?:/5?V8H5"JJ20J56E@$).MP,AU^5Y$,'M)@'YP.JW,8I@^/M[59.,7$/W"M=WV,4'FE3Y(.R8IOU^)P5VB"@/0QWM0FED@^?[M&-I!(X!_H3#C;[DJNU':6MOECE2&U1;14WL1DSJQ*W]%&42:*EZ?9`,AM*5"J=E8(&3\8V;B)`/_,I)F[_M`/(+*8H5%3?V^(9!$PB81,(F$3")A$PB81,(F$6.O(O^":8_G%:A_P`MKY`JM5WA[PLBLBIDPB81,(F$3"*A+JCYGPT0#[477]CW?[W_>S$99K7-8'==?YECLMA2C?E_F5LI]KWUNR)^5WF/6K`0J8)]?,.>(>E(F5/H/>90P]`+X]1'Y\TJ\LMF2$MD9O9ZC30GP'56MN7LD]2-VQWFO!O^K_57A;1;SQ80*D14X7KKNW;FS'._>R6WI&ZH&V@;\-?`=?94JUM^!Q#]/4U_&`LE>)%!WGZ@W.U?+#5;C*L)5KY42:-)H0(^>Q2E@M3%8B\ZLX/`PF\G@HJ8-8Z/8H-VS)BS9MFA3%M:MVK5!N@V*8>IBMTD2$31*8?$0*`=1R"*,PB81,(F$3")A$PB81,(F$3")A$MPB81,(F$3")A$PB81,(F$3")A$PBD]RKN-:]P?(;W40_T(X^%-5Q^3T[WZ5@NETF^[MQ4;DERU]@?['NM:;Q)^W[`J&`0]O7([O(!**:QFOJ3#J>H^/V_MR%2E`%6``!0`I0```````.@``>```!X``!D%%J.XAZS8R2:C/XFNLR33?'`C=`3+',*@$'MVJ7B?&)2;@W#G[:`MMW[-3XZUZ>Y:^S,YHS&*>']'0EIV[J4\/#JOF1VMNE%,JT1JU])='"9O=U86?M:+KPG8FBIY:KA1(B3P)$JP%1/T-Y9`/V=ABF,M^%\8X9TQK.&FQDD#Q-@=L#MJSK-)P9ZJ+Y%B\2`A&H)IK`50`%01+XV-MQGBTCY([B::.0W`87%]08Z4VC^MK7K77W*^FO\`-QQ.FCC!(94-/2OX-53R6S]YHMP5-K9S()D+`JI>[0TLQ$&2M\:=U9S((+OBK&78/`(BFB9-)8YQ`"$6#N.2X=PSB+WMC^ERLBBC-*2;JDGRTMI[]5:#*\C,;7/AB-3TI2GM53M;/NQI6;`^F*O!HRT96H:8A&\8PF9!1W,2S]M5!U'J1[1P[$'L-&M#J+E054^ZNDRB8I$SF-9_9[C#+B&*VN+CZ.^4M>-Y^&@MKOK[?FT]G573K[*LMII'0Q"XCC#V_#U)--OL(ZU_$I,K==Y'?(-E*DS0!W*[?*&ET&C#WIDX5.5N19P=)0G0>\@BH&2AX]Q9D?K>M(0M\Z`RT+16FNFOGX=5;NR&=>XPO;#1H'Q;.N@/2OMIU430KIMFP6F*B+-0_A=>M=11I!_8OADM'%0=C").`B01?*=R;I*;$Z0F,7M,D4`#J8>XX7!6UH^\LKMC=S\*RKK"`HIO`$.G@IQ](@$S#X^]2$S8')`'Y0(V9PK7@IG&`I.Y*'!W`-,E`,6O789+R)Y#Y3=EOWGRKTES>^M_>=6UH9"JCZKL'QK7;7_CHM:65G#P=3RJT8(AG\;)MM%:ULT?L]WYL"W&3=)3RR0.8"$3HK6HU;@C&2K`D!]RF(.&G]Z6O;_E.1.KM:)Y`A?)]I]/6OTC4%@SZIV:JY"QMRUSF,,D;$SI8E(?U"A)88A##&E>M=7>6M.#D4B9$3>+W)E(S0!P:/7X=\D,YZ)Z"OGCKI[EI\X\ZOH6&0^U7*`*;.C5RPMBJ0;=SRMDD%A/T(L(T;?F7F7I\8/4JL*HE3(1!8$CKM`I&E+T02,\(T3\Z4\K%85/5O(\FH2MIEUM;_?2=L6M\?457KDRQ5[LMF5Q%NG;S,)3*Y.(3)7$%A45=4ZAZNI+`$NG*=11FGT89(N

6EQCQ3Q49UI9G/-=UO9703Q*NA(3SI$X>CMIM.YN4`A\26RB-2Y=-9>_LK68J$+X$+6B#L`#E7O%O01I]4`/)]W3Y$JYZ:\3;M;4/*]DPYAM>T(Z]/E=`Z:JV'*KVL&0U-(':7;NCMTEBY5Q1::DORFS-*PMN!&D_LT'XC/=L02(`0KS(WK>W2-Z?-567IYMVK%J#E]=!K*YQFT?G?1UK&LZ1-#\5&(VG3R%"4B3MDMBU:XJ3MDEEA&'7N(UYP3Y(^B.M>FND^9+AX6,YE?\`DTB/-5R2,[I*%6J4MBFTW;&N25TUL$::85%WA[B5@PY0M=&]^*&),6!"(@\LL\>@!+H_?,M)>;HK3MO)ZWIGGE3T=&WCR$\GP^`QU-8\@K,4$M>7R=W9(=:QSE'0B42))"_N%`C64_MT2N8#]EF"!K7OT1YO5?E:FE%=OD\`4UQ?9O4=\RKG>,7I6Q,)G4:B$8'/R.S9+*6H+'4L#AS7&_OU,C5JENU2E6G;TR`Q0:#8BZ>[(^1O(7OLAD[6MH7HSF&2\W]%\E(RXUT5SP^SYGGK.\0NR(&\2&(R6"V?%DC*FD,5GL=0JP%J"MDI!B;^@6A#T8`>#]846]"=BSZG/VZW+%K>,?FF@F;"#6_P"K>O3>LN@_$YLIM5'LJ@Q,U-*$:8PQ];5!AS@Z$JA`WHA,A6I#"6_998]ZV,P01^[T]`ZUZ^N.@MZH8D2J0$(I"Z.LC$G=OS!:A6HTW;T>#>]IDPB&0+:G.0I=_4!1@1AV+6A"]VM]:WIK]$T9(2C2)S5!R=*F(.5F:-5&DD%%&J3=!T'1B@P`0C.,T$.M>HM[WZ:MR*[.`P&`P&`P&`P&`P&`P*.?-LQOKV?XGML;$]OGXGS%\9O#K^%:'%WTTM"+M5@[5O#I^/3*=-S4BV(.S51WL(*]=>X>O76%:R_?)=F.,W_NWM#BK^;^;7D^P6J'O#?(CFIU2)C%J%.\I`B4:V8G(T(1]$V/&G$_&;,;VO2[N)M77LRZ[+:^?0U?).B.BGCKZ8P=7!'F3;DB:LH-,^G?M@/#RED+,%>:D;"3=)2MQB%H8=G&!$)U:N\7\:E#=^V34QATC4E;I-ODWO)$7&'-A=T,DVJR"M$^\[1H=@T+WA]1/JB9=C',('X*_`[;[E7UA.T:Y)OGQNM7S?+5&87('^8PBK()''9#,90LB#]MCZJ1Z>Q\F`$6G&>27>]!!ZFRB;+W!P'OT]?HI&06`\]Q2@+4>\PT02MZ'@TU:&FG$G4O/_`($^>WN7TM,72W:M\AM=^26XM^?86W&/\^@U;*NAGNR'Z$M#"@^50ODL,A#\D5.2,D&S$AA:L(@Z^`>\'NWOUMGWC7OD,[0\-#IRG5W0,YI2J^]XY(+!Z'D-*6+7-8LLOD%7S(ANK!!N>QQ@?WMZ3-S4F6K7E8F2;9V/5JJ*P>T+MYL_0]XC%GSBN>?^7)I7Z&U7*NE*7]1M&K1='39S0E4D`7FIBO796PMC*&8/I"XSGY$O;/"=3[L'N^>3CSRMUE!?!'6_%ZVB.FG+L"8\=2&DZ"I1NHMBQI6W]&?W3891$8%8]:V#&XXZP!QKE2)]":Z;5KTB]L$D4IC$XC`%".'OJW_M`"CGZW/%HX>!KJJU:\G]GU)Q)RK8?*W7YU315WLR1T:[W#7$3L90O3Z"WA)4N63$G[HG]25"S3%G0Q68,*Z3]*!10UGE,P;G+1!+>MGT>H.&G$9L`1$`&$3JFKY\69XD/AX[Y98^T.C\\N%)F$(&AE;UCJZ+3M2V,&M;+2-Z`E0K4C"6`0MZ`#?M`'8M^FM;W@AKKRBDZ1'\;S!A#Z>H@ZV/=TY3%)89^TL30\,9D9DOUXNH>U;BNF1T')=.!4+9`M#;]L6DNW32LH(-^I7Q>\(=>OIK6L)"+??,IM&%]->%4]=(7M(^,Z7A?2/4B*3+HK3+/(H]:G.4_=$"-VYN!&VY3\Z@\@HS]0"]A)Y9RXONF3Y9>JZE\A/BH:K-MY2!8UA15L[FXWCJP2^HK.AKR%V9;CK20OY26/S"*,CPYH6%*^%$JER0D]O`KM+.)">(90_2N+J^1F^ES#Y,G6JN[.@^TN6N`$O-D1D?-JSDJY_6$MV4PV19W/D4D5E*I7'DA1!+1&@*D*8TK9:CT]YH=*2M&^-2FYW,/'Q^X%KF$5MAT4RNUP73UDDI>&])(I%K![3M*A\KB[V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.JH7(D@TQ:I8E3&+#M)TMA:A042-4>+T]"$P#!A$>=OUUZ!#Z[_RP,>-E[>),[G-"-UD*AE6@;EB!I0CTMJVM$9\8BB!N(F]&>`G?U,,`;L`-:WZ[_`)9=/JFKMB42,]"RU7*G^5'OR?;,GJA:>J7I$P&U4)4H4;ULTH/UP+`M>0N[?\`CZ9-31[VM`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/&6R)B;0I!KG=N2A7K@MJ(1JLD.E3@/M>PA1D?U[^51ZZ_W-?77\\NDCI&RU/KJK81E%'(T[8:D$N4&B]-$-:MMUVWMZ[9>OJ,8#OC#K_K?PQI]4UM1A+9DR5L/:_NE2I:XZ^_1N)@-[M+;MMJ4@\D_1(O31IFE.@_P`?;[OXXZ?VG5TRFV5*D;9IRD:9`O3.`E3EN/M9M($;BCT/8BFS6GD3FH3E>WTT88`031_7TV'UQT5RFQ)H5@>R7+:]W22`TDQVAPU_\9.2-7_^8.,QI*O7_C]=9`P&`P&`P&`P&`P&`P&`P&`P&`P&M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&M!_.Q@T((-C#H8O7VAV+6A"]/KOVAWOUWZ:P/"52J-(T>W!2_-!2'2X+7M7MPM3"3ZX"%$J:/QJE.W!]/3XO=OW:^@MB^N-?A^FFM';BK=AMB8UQ7MVFE:J/"(\2IMT$(=HS@'"&4,@80ZT+6P_U_];UQK/I[*]!*MW-Z$A.F1(4:-,D"(*5.E2D)R$P1;]1!3E$@`62$6_KO0=:]=Y!W,!@,!@,!@M,!@,!@,!@,!@,!@,!@,!@,!@,!@,#PW.3QMEUO;N_LS9Z:]?:N]?]Z6M17]8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`M8#`8#`8#`8#`8#`8#`8#`8'2/>JM[W@=43^Q@7?C!.[=^1^Q$YZ0:6$"6[;@Z]=K@I0CV)5LE*D(3E?369-(91K6M:UK6M:UKZ:UKZ:U_LUD5^X#`8#`8&.#EMT;*V^:-=TI7Z;^/\YLWY2@MWS>NBQ'C,+"'81[UO6MAV+7KK+I*:P[94A8CUM+>B*=VX:QU1:C3DWL!O?O#K8=:UO)HNL/Z+?V(YM,!:2]-)J,Q3]D6K+O^.AMJE*/6_]F\=TFD./^V3(5KT;WB:-6OY:0S.1;T'_`&:6MKUFO_@^N.Z?T-'[^AG;I_3^`51L?=0?_``_Y!A..%K_8/6_\\:_IM!H_/T[81._5/8J=0'7^Z!RAS:;Z_^&:@7-V]_P#0'+K7Z'5^_!:Q'T"XP%RUMK^'S-4@:A[_\(9+JZ`]?\]`U_LQ^W]3J?DK13_\`;Q6(N/I_^[I6X)/=_L^_MCOIK_IWD_:=3]4S8G7JJK-Q,_P`?Q4FC:W_;Z?>JVD6]?]&MXTCZFLFY^J)]M-+*_GY`O7Z_"T('$&O\`'?N;795O>M?Y:WET_6#7^)_O\Q>F.V35^AM>O?=H!DF2)1[_ZBXA>WB_Z0KDB?>L=MLFL/43V!!56]!(F47&/?\"_SK8`W?\/_`!0U(3/Y_P"&3236'O$/#0JUK:5TM;E.M_P`-D+DQVM^OIZ>FRS1:WZ^N325>@$01:T(.]"UO^&P[UO6_]F]?3`__37KO6O7?\`AK_'>!P"5I0`$8-2G`6$SXA#M$48>2:O1EG)DXE:DHQ40`Q.E!K0AJ3PM"'H12M&@;/0[_CQM%[WKW:*]^P^OUQI)K#HGS.*)DKHM.?VP"1E5!0NQ^E(!@;U@A_&%,JV7[]EGM;'KT]N_KZY=)GHFL.S^I63\AMJTN#M?IL_,_;A(4BWMM]/72H)@2=E"UO7\`MZ%L>_P##&D^JZNF7,60].T*T_P"54$/BT2!`,E@?1;^V%J=4]:UK7KO>_IK6M?KO>_\`#),Q6.ZW2((C7I'J:WH6M"#O6P[UK>MZMWZZWK?UUO6]?3>MZQ6U;UB])B:S&L3'6)B?>%F)B=)Z3#G*A@,!@,!@,!@,!M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!M@,!@,!@,!@,!@,!@,!@,!@,!@,!@-Z]?IOZZW]-ZW_'),1,:3Z'HC^Y2..5,MYJ&57,V:+DG^YX8F:1K3-L[@UJU)^U*,C_O5C(H;5_O``9'JGV0,OU(-&$>]M>,^5\3WE-GRM>S)DIWUK;2N2*Z_P#UMF*9[\5OTO&D^M+7K]R],RFZT8'SP\M0?H'RTQ^U^QYMV_P!:K\5T]Q+?W1-4#VQ.G)&L2*$Z(2L9._4M:+TMGRM11@LOG2HN=N>[>Z\FO6O,JWJ&@MU0NA,?BS_"$SO#TI*F:RZPGZ-LM]:L`V.7E+S79R%HDL82T0"S5RDA.,:(TZ\[S>;3\TOM/P-UP&I>BZ:Y\D,D8CVPME%5PKMDG[*C=C2_3DH3B'#6Z8K6Y`LVF]Z@L3B6,(!!"/T(Q;$_(_1DJ[RZ(MX#T0[L]B7-JDNMXS5'7B.TK#=X-)H(Q1*H:?:>5*/M4.:**J[1F;'J:SO6VAR9&GV3CVH.NS:-OUP)LGJ1'QU(Z*9(\Q/5XU[?)4YF%9R:$*M8TW/JAJEKLQSN&'H""VM:;IP^X(,+$``A_&71D*C_)DVRJ?]#5+U)SW9/$MFM\ZT>@ZCD3#:DHKJ>LK]S4X&2),=:;),:FD[2FZM+AJ@9$CCI3^W$R.Q)2GH6)N2=F+E,NQQJ_1OZO+R722O^J+)XOHWCM*^>I;YKNH:TNP])!'^L837XX//U\Z;U)\AL>QY3'V.*.K6JA8"$2$X)ZU\5+MM`1D[*2K#B*FBZX5Y$5MY\C4CU'RMRI>?03E>3L[QM#4*%PK.N9#6$CB+A*6M"P$5T2NP9HSQ&%H83+88N:%!Z8]S.5+_`(0I2#@&Z&$C$Y_E[A$6Y,[&Z.MCMGRVZNGW!_:;Y6M5AL:SGBW;&YYGG/RD^.J+3_K[!K=3TRSU6VF)7$QB5O)-6CE&I'(XA-:ILJ)2%T@$VBM\7R%EB(CCQ?T+:UY>9OJ%+:5-W)S6_POQY./S"5'+Z:M'D'K'ESDJR*SE;O6=H5QM9U7OSI'93&GS;"N3[4HSB5"!Q1&D'`"+0!#(DO$NA:_KWK&J6J;S;H\ERB7BM!.Z(D[$GG"1QYG%`87/8@DDLOF",LL2A:N95J5(0$PX990-G'FA#KM8A!#KU^N]:P/F_?^&NKU?]ME37$Z:GGZCT_PX+L@-M!3Z(8R%^B1&!,*/V4/T6%2%1>1NU>ZN_>NY7SVGY!6WYMXY(;3G*1\@L.$V"^0FQ8Q);3.A0;AW$7%\:6NPD#V\D/K@A;0.30WMBE(E^]M5JRU6M#HU=QOQV]'3.+D2ZRH3KGD6RNV.T>@.G8)9+]91\%LUG56MW*:H4'W+-7BQ8S*%?SOR@1B-A(8V=/I*D(5*-EEY%U;HWSE/H)7VKYI[.3ULMX&03ISA3G^J*)D/YB-!3V%842J>^(](XT@2C>@N+4H:GF5-Y`SG$E&F%M4$0M#!!T,0:FO2$0^K>?[-YV\!'$]LR5G:ZXZN\3E\X8$/UDI`1`1`1`1`M1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1`1;S1^UQ:MD!$M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%^,B/'EL/193#,F-(;6R_'D-H>8M>:H=/;=@N6BLC1_RMK1_6#\YM'^D/*@QASF5L/)^1:2472ZTOS2M!J0HOM$C,:4=W[-W9L#/S[5WMCKO%;BMC22WN8S'(/0X5Z/8[M;(PN8\=6N(4IRPUMQS+:9'4X=CR678\AA9MO1WVULOLN)/A3;K3B4N-K2?F1D1C69>M6=WC[N3'Y"*6WOX7EDD4K'1R1N'0M>QX#F.![0X`A9VCDCFC;-"YKX7"K7-(M+2/2"*@CUA?F/,N:`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`B`BM`B`B`BWFC]KBU;("("("("("("("+Y6M#:%..+2A""-2UK424)21=J6:8_ZTW$9#67UB.IM914DB%?,H+QZ3BK5[K.,B]K2R6KV-C3;S?\`PO>8-A&;,[-N-JX0@-MM\DQOH,+G>#F&1LCNZ`*36U.>]M9?3;;A8['7QZ:NKX"?YP&IG^4"!^6HPM3H,VLE.P;*'*KYK"C0]#FQW8LEI1'P9+8?0AQ/B7R#6OFL)F=MY.7";BM+JPMS,#M,D%Q$^&9A'98JZC#8-U6;96]\MO[+OA,;CI/^2YGP*+.6:=V1A9N*NL6L%0VMN3.TK$?:M;T^/"U287JFP1D7/[U+9E[2&LCE+RD>8;AYTDN\MLWYQ,?;>6;?M?;2GY1FM]?ACI6DS8W#O`6=]O\C;,W*&MQE_"+EW^JE/A25]&E]-7^27!8RYM+Q+VD?!E[2/Y#+S(Q'"HJ1WCM]7PJ]T!$!$!$!$!$!$!$!$!$!$!$!$!$!$!M$!$!$!%P9D7F9%^D?"X-ZN("4)[%D'%-5[!S52#Q[%K.3&6HB^T9+7V?6)(_MVCG3C886DB\?H&H_D(9ZXO\`+%SSS'(P[!VSDKG'/;FX\.-PM';2,O=Z`2K1SV_-H[9!_7%_`R8#^K:?$E/\`D,U.'QT'K4I,-[/5&;4K/,DXM+Z*EU&.I\3]IMO6TQODC+R/TV/T*&S'B+^$K(3%D^;]P@-]ESK'%#XRR2]G9MT]!\*W].F3L*P5N/S%@:H-JV77J!-2WTJI]HN=M2+7'[;!K!]3SV,^C.IU.*-2RIYRUH>BD9GSZF"`.&M_R5WW-P6'PX_E=ZC#JMG\$[N@[D::)M'N\[D]2R[UNW1.59DS`B[6U_>KP?9**QE$2!:VM+4*-8U&5PH"/H5T?)*N22UL)_=M2V7TM\-D@B\D\?AOH/DE>ZWE\5E3\H=JVM0CI7>@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@M=J+&N4Z@UOF/6N\Q.KI7I@N1-Y[^%QMB=\.EVMI/QM6"@AWC_$;9_XB6(&W^(>.Y6*2N&J9HWKDI8U6GV3NM+1+8DD)4=*BC&&Z#;4MKKOC1;^W$7@_D3Y=E=@4MRGS%?-)6C(+90^_2]@WVM!RPG$9*\CMUF[7I.[!9OJ&.;)1EE'(Y4MCP0V(_`V9Z_J1;MOE+Y??G&=Q_)M728T'VG>G+5E/NDZ;M!]+_K`,&8_65(GUI2LG0M.J527UL\!?5EGY$D@M@T+U+Z?$FVPM\>FRMHBCKOSY)Y/=_W55WT\UKRPHQ7EM?1K6AML^DL.E`4?'I)+>GTIDO7!M^6%,FMHV`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>M`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#MP'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`M>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!XM#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/M`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!MX#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@M/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\M!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'M@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`M\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#PM'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>M`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#P'@/`>`\!X#MP*V]5U0G;%0GF.UE7/5SB)M#$U8'Z/L^153)W3\+&S>K4:4.1M5-T1CZBCKYM562ON04612WVUSE/'@W4]X\KRZ:![_`.E)OO"3M,BF'$71&6R`[UZ9Y1LB/U)>,J3J][,J5YDNZP=)$W;*QR,[W%`9H###UAP2M1M!OZ@L]3ZH6*^OKLJ6=C128+MMB+@C6G2,"GMCH09WUW@$A"9L&-AQRSK50N68"7'M3;_-JHKNHW%&XR?[&KVJ%GTM'KTY[KM@#:-'+=>@9\,@TJC/4%CU41A$E;S!S!(7,28@0UE#EC)XF1&)L#NHY1#=?\M-]CXPG6J>R.@K@86Q=\;J&A@/),*D?2D%BLXL7H`W!K`)E^;Y%.("0L.;L%JMH+P.#5/*K(KT@RRMN7!K?[XLL"JJG/7E9R8^.#!`M83)*-CFR[=!LHLD$4SH.9HNMA1=1I]@YIW!:]F6E6C==IQ]ELXX&W8[2IUG4MS\+X!>JY1^VKM)]N*SKJBFH[V2PZVPGC?4I"&D"-19XUJ>"6(R6QJ=,CMY$0;NFC;M\;5-)RN6CEIV3+>P?Y']UUVQTA!V+VFXW5-*55,!_1/04?/5C3]G5+3\K`36U(YHTP,;2%8R-&$VK]7"FVKEF@6GXJC\Y=@MH4/55%V+:SNVIF-A](_=I?9>P&Z^01>N'ZBP"PY)F/&$V4M^)0D!'-89MGLMAE;Y35LOHT54U6\%$7:_9/UY>XOCTKSQ&>>PI:1_8'QQ\21%8B?V-W(UW+7JSH6!.>)(]UXEQV6FRMJ&DK]6-:]`LN5RETC:V3M@"L,WKD5>[W+#]6H?U..`J"A3777;*;'^U%S"+;94!#ZDB):NZ6OBM>*Y;&P\OO.:WFYE.'YJRBIR!LY#9595!*$9C'$8PZ:R`;JW=,WP0PS7SMKH[7M:("CH9]R"R1:>C'&C"=&WDN*JNRJ6-7SA0DYVW4VRNMIG8-#`8-UFC+X$%462&FVN=4M,8#SU52]045'G\1I6KX!M4L5*2(O+B,:K>(@H6!>2`\!X#P'@/`JMU_P!'O^9ZRCDAC,*0L:R;.MNK*%J&$D)#F(`#MG7!M+&45CF\LEN@B0+QJ'@DEW!0H[1'OG6K%BIHW;K.-TD]@H=-_LCZ(J=K:573?MFNN)+U+6%[\9U,SBL"N8NWIZR(UV[+G4-K*6G#J!Y-XNNZ_P"+E[XF,=`1M9E'8=T$=M.,`;IMDJ%RRX?3UFVQ5$G*V%6K2%BHQ_C2S9I!2"+,:D?>O$&J+1P];[X7W3:!8J"_M9';TH5HV[2E#P,?Q?TKTKMS%5LP'VDIR5D0HS]B$SNL]U58KG>$!:WO#%7"K2BT#F`NSH=2\>L\I'1CUJ"P*8IM=M&GY`W1[MO%YOI/!%HQ^F.0A9N_A-H-2+MJ?$^(138=K(GSD@@*49X'XU9;$,8J(VN"D^A['K;LB?7T1Z4TZ3H+Z@.,+'KM[,!L.UHJ%`=O@ZSZ=D,^G,(CM;EA\1F-M"+$C`U-35)`CIJBKJWV;[(O/:H'M2SD2JB=#]RV9!8FXN%:J["X?YRN*7KV/-;+L46?Z.?VK>,;G4TS(;`*FVPVQM)+%6`O\`>M1ZC31=-NT54:Z>U/;(Y5'R?_Z(+CP"`62SOZX.>CT_MJ9%D/NH^WL&LI=RO60VP3,+V7R9KD\_UN\:_9)MD,*%6#E'+5JDDTPFEX/))M'2-17QS.[[CK?BI7HI%A+N`>9[37V4F-TVR=?VEMTC8\.OZ]Z-!;2KG2;5E:#;-?[]#1:IMI.=2JTG"\-GB@J*:ZI"F'RM5'P?JRV"9"#=P._K0_P"I$SRP,X[JZ2R9N->]M(D?S>GHCT`PEA?%-Z6^YWL8I:>>?1!+^:M`&=MGBN1#=YIN44WTR(^*0.G[EME/3VWV.3'G.0=*8K,_3WU5Q&L)]#XWN,YVSC'@9W7;7?77?3;7?3?7&VNVNN-MM=L9]P-Q\!X'B>DAPW5ML1?LA^KQZU&L]GKI!KJ[(OME,(LF#;*ZB>%WKM7/M22U]=U-OZ:XSGP/2JJD@DHNNHFBBBGNJLLKOJFDDDGMKG=1113?.--$]-,9SG.`\!X#P'@8MPT:#1H.6D4B+#`$?`C7QDX=-/VHH.&$#&RKTD5+$WRJ#(OTS87E^#M[KM'%,7K^CV^U;2_OS:MA3]JMP?[30GVGWH7^,\J\H;E6"W;?,F_*3[^S9B[S?7TC._>5/32;).0^IHGMV-3:.[(/%I=$XPY2*0Q]M13,EI(=5VHZK"A4.A(&9T=TGX)ZKYE@\F_/0RAZMV'7C6]ZYY9QC*XCN[V;-NVKN3&W";=O4XK6JI?5&+K3KV[-'H+Q=Y(VSRKQ6M/+MHQLK%V^=^Y:C&^H*VL\!0]Z_P";9(?/\-9NG_[>M?W%\F\B_C[7K3_277[^O>[>KNTH?ZT>=YRYUO&=%IM%=[3F/*#TSLN$$7V;(M*,%Y^7C/VOQ]R[&VO@?ACR]JS.[ZU_\`Q_I+#U&8;*JP8*QFKRQR:.KW\:-VM+BU*#QG-JH92!(!:IM)$1O0#`@4E_SA$'>];UO6O)/EW;\?[=O+6[\"YSQF6YY6'EW+F)*[G7\?$RLM.Y.4\6^[=BS&]][WO>?U3ZG5I72Q/RWD]X4IUSP!`'YZ#\P?("8-32';0/3IJ61G;9&]Z#(G'3\U_@,`MI2%M^@O2S\K\=KWM"J*.\'B+_P`HP(_^46M[`P:N[VK*SHTV2N/21(D:WR=V-7#"M"0'I&1@_K@&.SVMWJNJZ*FSBPY_%(?$"#V5,;(GQZ1(VH!TAD#;%&76U0S=E[`X2-X3(P#UY!]QMP=;WK`/:VVA#'#3V:`92UOK(^?N&F5Y:GC]I##U]QQOEP$ULI^UA'\4IF@AWO?GS@$E:M6$"D)\>*=PGZ1M1E\E;G)$Y0SH4S-\=6LZ-V1O4R+^4=:7Q.%\(4?@J%!:K:30S]`^HL0M`8FAMZ+J)RM4NGD4M;5,I501AL)L6DK6XR,O31))1)(@UMS(_EK1)':1F/$36?)"1M\S@E`T/]=;\:`[V,7C3DS1/3E%[/@SR@CD[=JP?%222M7TM=AL;RKC[G#5@SM5)>BI"G>D!R?2;_O#3"]_7H6OUP#/UKXRMJM`@M>C8\^V.TNM9G-EI`,0]7TN85L9EJERJ=):%JD)91HA$4IX8OQ_P"B''JI+>36WS]LZLKVSX96M@&AB,KW5%0J&'T2XP=XF:B`JK20R214O-IBZ[2(UW[$5+7DO>RQDEC4B%)#XMRX]L/G"/RAHETCASPH>N;.6:91G1P]Y-+*D=&5Q+X=)G-1^Y-"`069S?KSL:DN8:-8JU:$I([.BA*@2`M-4'`+#LPP.A#&$.OUWK6?EC8N3FWXXV';N7X[MD6,7;[23G=O3C;MP3:2:,6_&@@#O>]YVM[C')V[M_;M\Z%I+JY6+J2_%N-$8OB>2?'>??CBX6_;+>R9ND80SIM0HDS6V%FJ1A_%;#S!C\?$.@>/U$((=]_QWC6Z\IS9X&T1C*_;M2N2U24(J$6MDVV^G>27[?A4P;G_`)%XOXTVBUO?*KMRWAW\J&/;5NW*[.=V]:UG*$)7M)*$$Y3DZ)+JVWV27JV?G=NVK%J5Z]*,+,(N4I2:48Q2JVV^B275M]$NK-=,!M]JO(5HW$Q4Q7\@GAYL'/\7\LVS:)[QGV[%JU;M>Y*W*['W5#XN'_DKJKTI7H:(V3[MDO%W(^4VN*;'?R\G)OY/Z>W?ACW/TTKK[15QTE1]]6C1I^K5H^HV!R231R&LM+K*9]:UO>]:S];%BM[DWX8UE:KUR:C%?&4G1+]K9\N;F8VW85[M=MR'C^X\8W.6T;HH+-A&,FHR4DE):EU7K1IT,8X'SK8?(W';?*M>-.]+:;MRY"+N0=N3=N3A*B;?12354^Z:[IHSKG2&8C`&`,`8`P!@&*R+QI]M5;"RB4UCQ$^XFYB#)5];DO*4R6(V,9:8\+@I:@CV>27M,M)-^(O`_I-`9\?@M+0M]I+9=VAMJ:^%4UW,;M\PXO=Y+/AUO/QI^.5[`YO>YD\5JZ/MZV(R^O[/CR,AQ>ZTM&N)6T3FO)P@;%)Z5.ZZ9).Q$;4)!FDZ5)!FDZ,*$/1@M1"&RCBGV-=-5#?M$][=D48NK"VN9[+YZ1,7*E!OD%,80D:+%,%1OU@]_S)?Z\VKH+J/E@JK/73=U1MV!`JXH3GN80L%J,]8PJ1P0N13I[DE@/@8S-=1]V"2B;&)&F8BAJU9QWWBTE+M)"ID+MCUY]Y]U)IISAOJ;7=C]L?`M$G_8?P\_=D12E)'55L_Z#=+/,TT:FMT8'B*SN&FN+2*2MU]/(T\*&]T3DJDZ@(=EFECWLO91@&$:5X9ZTGG7-5=G^PV]Z4L>8\V0NPHCSM337-%9R^OZD@C];38WQ^R+:E#K8LRF!)\M:,T9_'!:D_.BZ(@G4%"WM%SI9Z=6IKZ[:XEU92T+%,YDLLP95;*J7-2H99P$KLVZ5:4)31`&$M04`6PMBUKQL0TF./JY]B=T4;!."NJNVZ*G/!\-,K^.S-TKJA)9$.KN@JAJIT9'&)59M8DJ=+&>JXAY+P5&D"=]=V=M-7N!!(]?RB/.$,7I^TQ9>5>=22/WY6$=Q;=-JVD%^XW;==+;#I>SX>LZ4M%E/A,Y:HV_1::1LMH-"2O:G1E6EJ4RI/MLDPLY,A)F,>F,.+MIRL[EING+-YWE;#?M:2JQZ[EM7V+.+DX'K2W;9MBVT.):`I&%/HX!A>Q_/X^`X%>AA6$\+]/T>K]B4M[YXZ&K"&VYU_U?&^DJV>)Q4[I/87$&5GA-;0][K>PHX7+(ZY/*>6((6K3F.+M4N1*4`%H#R="-+^&P.UQ9PI>=9=8]"]V=5V'1S_?]]5E7=,G0SF&M9)6U0,DM)KEX>I"FD3^?-)-)YC8UF/SH];+-=7`9.T3>G+2%:&5\?K$+\]C_`!?:/6C%MS7,*#M"&U5?_`"-TE%.DZF=;+B3K-JQD3NR1J5PUXAL]8V!ZC\A"QOC#+S__M`!2!4!40:4'X:U\OF`#`EP\%=JNMRT%W31?1M!PCO.%\^GMA:\7R8,]+:RHDV6&39M?J(9.1FJV=>4[N"H9!FR3_P"3Y:$+4SEP_P`06;2%ML]"]:]37#&KTZ^Z?3P&.S-_KZ$K*[J*L:MJM(Z)8%4E2Q1V?Y/(`L2%4]*U[MBY.2XU:ZKC]&&`!LOR8(9#ZU@7?DE?HZYV[RTQQ!3$WR*V/4_4M,36?QM\M6N:H`T$R8Y179PI13K,_$CC=*.Z.R7!J2-J%>M-2@2E$F:&8/[`C%J9PYP]?W7C%[`&;V$];=15K;8S]@L8+[&0PN:PEY:YS'Y`R[V4`X_:-66((3!`"$83!4_B;8M>=:UH6_M._&O.]:\:WOQ^N]:\[\>=X(?@MR`+PD3G+FX"\L!2X*!686)0D"M*+"$W18@Z,"'6A>=:U@'?P!@#`&`M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`ZJXY0F1+%"1&8XMJDZ50X^&M:EHIW/H_`$C7M[.$6P"4H5C^!289Y"$1)>]:UH>]:P*=:$1>RO83W33WM7YBMY_I7E6S[9IZ54)?,M)KF.6-S?&@=,N+0R50[%39@?K`>V]YKPJB')]5-RU&YMKVH;R:NT:F)5$@T/0&T&NNT&:>]I6IQ,HKJ21F=5+SI3W0DAD:]V8U[(:DMQM]D\?*AR:)W'RWJ._NL]2M]4M)T%I1W!0?6O3\XZ\IB;U-CD\ZM3F/N1J/V.]2L4'DC0DAE;I)9?BJQ[+;XN\RE.@F=]=9*OMM>MH61&Z'R!K%'S9"CULQ8E3E'_?K9(C-:'\1#NEADQ4B'#T8Y'&G](I#^0O*T1]^@'[*,T,(85OJ;_`*C(T\0^D*>AM\D1Z0/\`%ZJKZ-/S?H\A3I$\,D1:&MT1Z4I#3DJC29:F,!]A0QEC^/D(MZWKM>4XL\^'-+'[0/6_SM/\`U[5AP$OZ=21F9WB7R5U+'+VIF&TZJ@5O3F63J*.%M_,$SDC7940?:Z=)D>%U2-C4Z:PA4P7[*JWN;I+W$P2%W^/H5`$`$;D]:_";-F+E1"D\M*$/0N*HN&>IHS_;MNWMQ"^5>8BZ@E]+=NQ:.UA_54+4&N+]:]IW-(H`WAE">0F0U.*0LTH0G!&:XM%E$?D:">(L81A"#[U,]M/)/0*7N?U#6Z?`1`KSF7@^^Z=N^0ZD,7$"%6-,(+M1+-'(Z-O"];=7P3FXQ)Q+"I;B%:0O\;8C#0!$7L8$=.+6GVM^L7+U_P;@`M'1T8AESVDOYWZN3]"U1`:24TO:EJR"Q4CI=3*\.!]NQR90$$M6%*VQJ8G,;HM).6!,;X'I0(.CZFP/W4S-+`_5+W3!Q.//LNA2!]/BQ4S`;-'F3D,P%!F]%H!K]*A[T$G>\!=S2I0D+EWK!7KU(A]"^F_M".T-P+5W-T2R'G^(2^%P.8/%62FCY73MY0X"Y6"[Q^(*%T-VZ)3-(5*Y.(\G7@`O`1;U3B5YHI;HNP?:_P`O=HR>E'*MM:U2>LJRJLL=&[36"2!RK6ZYUA'+JE/#$Y=^.]1-M#N-@Z='S:I35#3+EL[;XD)F$Y[C8"$\KMH>F6GO[B6QNRJXL[GV0U=R[R[*"YB8FF#2X1!-1%?,D1=8QM+',;:PZ1/#WO]J)5+5I@2MZ.R%-H!G6,6X3]RGLZM/H*I^@D%!V_6'#$:9^AMH)1ED6E7+!-H)5$U5ZAAM!BQ::NR7>J7OB^E%*VK#0]S>XBI.M*?II]A+XGM%II-UZ@YN9V"6RN`)4JE\MC3M+&R$JG]8F.("8G1G`.,W\!?+`-P"J)2P7O+Z@E@8K)A11P]/==1IOE.H^M[[C2^2E=%6BL-CB)_P!(_P!I5OY2,X!PD19PE(2AZ'L'QWK>!Z&J)IAMBU[_M`&__`*89P^55:RI-RKV%Q]?MZ15AKJ6/=C0JJ:^NJPS)G*#ZZ0M1LP6EL"1\M3*3B24@SM)A_;\?AK8LA?4V^K.7>\NF_:WS3.C^FNE)5$XCSTT7')*%Z8J*Z)\_S.+SJIA5?0%J('I[EMK/)!(GYN5.!;@2Z%&@,+!Y^((7\"M%/X.V'6M_+Q@&P*W:LFT[]V-BDL;0_M+1-O1_.:O06)IE=RXH@FC_P!3+RFMMK/E!*3]J_?4"=?I:%']^U84^MFA+^'\V`:5GCJDQ@_M^[#]6`.5^K5W=E2\KMSSGZSZ,8.&,I1Z94F/`6,RB&24EUA#2FB?2!:EVF#QKW?/SW%W]E:)=T?RXMBSX[,3DVMDIM;FWE*&H%:J/.JQ(0D?43IFO;*]>J#L_U[7GT]'+#E5`,'J!A'KPFMWUS74ZN)LJ3H"K)E%)P:=)VFMNX])Y8U1BS6]O-1H%X$)@3U"0(!^`@&(`=^A^.?T%F=G6M_HV1VYRM.*Q_G%90MK5-$)M$*;RJ31EK9I`HD4F9@E-25@-=%`D)IBY5I*G2G[T!LM?;[C_`*T/;=WM@Z'YIOI\2WM7TV-%V$AN:P[:L1E=)-#:MQYV3LD=;W!460)4XJ$A9AHO@5]FPCT$#![9[MI.#'/ER===?UO8#75U1VO'*4N]G?ZDGK!9]%V')WYKCK>U6Y6CLS))3#T13@M])?N7&$C1A`;_*:,01A"+0E]U+U_1_'E3.B','/UG]`JJ4C;VEVO9G:VU]?,3DTPO;HVA$J)2'J-N`TNMM'?C_`%B`(0&O_P!V74U>=`^E-7TIRQ;9LDKNP[@Y/6P^Q($[O5JD!W3U=,MKTVG#*VT2!DPZ"]U/N\]5M\NY_;'^D^I;^PO[9_-_(?M8WV?^UG_`(+X7S/S/Q/ROA>S\K`,RL&]ZP#I*:MB&7U457WA7*M:OMK^X:^AUG0ARX@I/61*Q(?&IU%UBI&H;U2J.RMUE1/[(I4H%8"E:$\]MMG)5+0FMM39F::BF=1,%;.T=C#R>A;"D*"9&KSWC1JI6K5A%K9198P!)%J>9QMXL:SF_DJ@?D756'*$2B)QZ/*I!09+8B.KR>71`8=9%:U?>[\N,6!5@F5>UO:MCHTH@!3CU[-)S-&`V5L(PJ9^/>[XO?5XW?QAVR_GGMAFU\5F]417]_M0AWM-ABK3!?]5Z[)ESS&EU=S)_B$>;DSL$1CJUN)R$D\Q'\0._4*]ILI@[$\MQB%Q*-R.7N]@R!@C;(S/D\?T+&V/DT=VUM3(W*5.[;&6UFCC>Y/ZPD:H\A`DM3(RC#=A)*`7H(="&MZE?%C6=*^0V\^^VNPY0]G6R@E:R(T\S1WH`6I5(SPC3,NLT?-#5WI8S/MQ]$NEVKIVN:,1TC5_P"T2"3(>BTG21L0LBXA*?VGLZ&$3(2P2$/RS2X$'&ICME2I`Q0F"%&J(!K030>N"%=:Q\4=QMMPKJ"N*SABR)NU/2VHC@35!%%2EQE%H'()`D./E*A5O0B4`TY#>FVMM5'#%J9;'/&[T/24@L>/\A^069*TE=I255,K014IM9M)ND3*M(7)1'Y6SJ69P4-Z\LH6F]X3%J?CIE`0;^`I``>@[]OI@A0&HO'MSTQ%X)):GN[R-6G?U5:YXGG.M=0U72M4UV-H9IE&4\.;YY:LBCFEK[[)A>35P(ED\=HJN4=#5E4T2,AMTBI)]I$.IF**KW!V?I\C8EZ(?VP`],@^$B&22U)Q*CC\"IGL.\:,N@;YW='(MWU;*"^;NY%/14U>*%5/3"A,2*%2"/'$D)RMS5@]&*#-!#@5,\K+QTL%;61X][%(M1\=U/`7(\TY09&L^,MR0FS6V8Q.FXJ;M-7E24Y&CCC@A*J`L\*).!248-4!A$W7O]7V?TA:G0%=P%3'T#(VT'],FBK8M+J5#7->657Z>4L8S71..4K'8FQAJC$JGY4LH:0(`F;T9L00MJ8OWAXG(+W/SOSK1;MN>O74Q(X[+-,V0,LH>@&Z+]@@3H2QTSP..U)ASQP;10TO7M>-["CI*TJWL]FK6+5Y%599"2-NM:ZOA%F+')U=G,!KFQLG_NNVZ?`WO>M!4V-UYR&QUWV9??8#=+EBA;>=)4'2AM=A8T:)EB390[I9;DVNS-566+7]C(XE#Z\CB\\U4WOKE!=A5JGA\=%MH1KAB+,"`HLG`KV&66;X[F"RK5[RM)1:+VT*^Z..(IR"\M">--ZHBN6J+,ESMLI4Y:59KF4.0.*L%Q&F;1'EIR@"0AU\46C=_#$.;77C[8J]NSBZZ";.>75;QMMQE)^.VEB/CB!,FGC5)BJK^28#R),F[IIPG02U,8J.-1*E>=WR;0-37Y:A6]KG&*Z)2.H4Y:9:M:(TXO0/H-E4^Y,:IYVCSKV0?-7%M=^>JAORI4$$)9TJALDZ6]E]9KUKTL>QKM2U;:HC@JV+"4260:%1\UO8AE_#]!B%1IUXFHQ.*7[%IPZ[9*W).O.[8?W$Z/MQ,.9U"J"O$2FM#S,%=-B$QV+(>FE%X?(58T]L-^4&1Y`0.L#YU1$-HXYL9BPN)H9(4VHX@%Q`:HVEV88?LK8M=!!\00A79W\4M);S]TAQCS`SHJMZ)!5\2G#=.*ZFMSAB$JJ.3VQ1W;?9+:%-12#YOY\#BG4LVMD.D>B-DB*,V9\30M>W8O50UFW!X3I=8T+Z]Y_AW?-P5)Q[U[.[=M^4\_1BK:MX#V\K(D62C,5^XQ&)S"E/4%FA4MQ>'CZF,MXOGE_I6C>H)+SU;7/51OO/D@(JL5RBK+:DQ:E_J!3,82SH4;X%*A7G*-)]F)#T1X@&E`2?4GC3CMU42+QH2!+;3X\#\;O.5DA""I\;6X"MXOI6T>HN/.PWKE*9]!1^",_0L1>*3A%^UO8SMS6#,;&()8C3'Y2]Q1SA%B-,1-"U*%:9>>@H$:0V]J?L*R[>IN$V'&I-:-!J(4EN6#M2[2A_KE18T?,E4&)DR30-?(F2>M.DB5I=>HO>2'>_H^Y@$LX`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#M`&`,`T]=,6?TO?'D,C7C[H3H!TY/A4,Y,_>RNFWH3!:^G-NS$.>:>D?*(Y0&%]'/O2]EV_P!NN-,\^Q25Q$=@(-'%L*DU:UQ7+Q+)4Z+BY&_-+JN`46G9]K]J#R33`,:H?I[HPSQ[JMKIZ:\E5H5F*VNRYU7%`75^Y[6CYMTG2$$\@C'>K)9-7ZIBO:XA-)S^M*5%=D5=Z$=8VW%6!N)!*;MU3*K2REU>U:PH8%@S0G[]A0%:VKO?J]UH-JK>!3^)PJ[^H?-WTWP-!KH_P!+M8*>DI*GX;9UL/:V7M\%0-;-$YU8C+75;&M[:;S0G3//%\Q"B^*N$ZPI:MH+/:JB]*4Q.(U,Y+S>E;V646/THGQ?U1G&D7%CT:7LL8P;`+7M%O7IO!#L,`8`P!@#`&`,`8`P!@#`&`,`8`MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8M`P!@#`&`,`8!0+J7@=GZ"MZN^DJXOBZ.4NF:UA,@JULN>D#H(O62FII.[HY$MYUE8T)M&&3Z"3:*)I*A`YMX5"`"INM62B&P9-%$1[D0V(Q21?LP`S!"T0(8"A!7B;*^DN-:\(XP)W"J>?(MQVNTW'(!2!H;U\=/NBHH/$8&%`T*U93P^B>'EG5%#&B*.TDT#0SM@"(.]TG4M5*\C-33*5T\RUFCKFY.KZYL*4].Q%P?'%5-:A?G(MAXNJ"P*$)$)PSTFW1S,3NRY5\-0F2$Z&IV#,Q\5/,-]\_P!H](.9U-3[D#C*M4QZJV^@^-;)Z!9NA7*O;'9#9\'ODF][:?(U62^/1NWWJ*%YVH=RI^'SF[M(TC5(X5:ET/4GGQ;WZ:T'6M?;^;!5M/MG&XO\;??O4_BAY.YX)\C36PW>=I[T'!.)._HS0/&G3]P3"[)1!'FA4\\O6AI39R@M3:*/F^Q5(F?^*B3D%429,Z2>8VN%1-W5]E=ORAMA3"0-1Q!J%ACPE2PXM$H&JWLL*ED>G?')TQOM!V[]\?'4$&YWO"S*KC=,]"PM.Z*F5V[35R1F$JC#X)*E*%FE$4DD9GD.3#TD)4ICQ`4(P!*]20B4:4B'MOWQMC7CU3XY)[R-T3VB]65T5,;$9;K:ND]U9'XU&8+9$0GT?L*#1N)U&R.Q:='54M651TMM*1FN9S@:G.-4F*!'"]FA:F?*Z-\N2RC8/HKNGFIJZ@BUDOT@D;BEY0M7K>>[(K-?'$#,SUO(HLJLDJQ61U:'M*:\_?S2\)#C#U&TNTVTX0X&!VG`?!5MF\WVWU9U9TI=,4NSJKLASJ\=FNE85J*I*AB,6IJ-.$5@,2@T152*5/B\U.A2_QOSGO>:/"0L\I*2G.Z%P3J4SPSB4H=_#L[1H0J1K0GCBZMDM79E7]M^13JVONB)SS5!9S!N8:UI2FUE.U=!G*RT1+)/K:DR)[E\R=7^Q)+&BM-(=%EFE(D0-^XK>_87H`=!KH[QY0@G3_`.\3\7P.&OSF).CH&-],]X0!LT`[-U$OZE9ZSMC@4[?'XRN6*;PMU5=W_=QZ#H^RQ3^JKS!'%,C5L"20P^0U]8T;&W-SPP*=(9E$Y&,)NRS]:T>DM(]0[#K?H(CN+?\4U*VKXWJW\="&2R&N8]2T/I]+3=LPU,F*F-=6G2&VIRA-NMM:%0?](L?!R9M,6."H[(W=O:'MDUGV!TVDCZAX7?5&_``LHK85Q)BJ?K&VJ,[AXFH'E?RA5!Y2X?T=:;PT=#TGM`:+YC;G:H:B*B[B[O/2#A:/)S.PM4:%&%R0@%]["."64$0_78`Z#9_%M/%])(W!O,)$1W`QJC_)_-K;ED:7!AZ\LJH2K+I4NJDJ-]3[?Q#EPVA;K:LP2M_J@=+;I2RY%634='H1:#-N)3."2^&3EKCM)OT"CX%!R9>#]M_;K>/6BZR^&1[`*_LT:S6MBP:WO?KO[/3+ZT3=*XF,LNDG2CG2M#79XQNUIWWGSS*^A)7#(M"V!;T'=L`JM-+%#7M1J0U/6LG#%XY+7XQY6+!#D3RN2+=*-I?B2>A(=EEA^W6=FXLRUGAS4MH:9"Y.=Y9:U.YO4\VY..\XJE,$FJ5QQQ.+TB]+4;$K\XI0[R2CVQ3:7RU3J;M#PK1"WZ!WL6_3>_0/KO?IK\N_36OR:SK'K1=9RWA4>0K1#WH(/40M_D"'U%OM?^36M;WO'K1=8\-%8O8C7MTDE36.0[JH=('B-OL25NR5C?W2-+E6F21HF]V3IMNS,H"2,PH.CBPZM,!Z@%K>;[5O&:)J%S2]12AG;36]%24J5BI+&+:V-=.!H9-V,]EXYFPZVI;,&MMC:Z4GT=1.>U1H0:&((P@%_R1["+0-_Y!;UZ;SCO6JZS&C6G2>OZ__`#M?MIR^M"^%0^O\`\[7ZM!X5#Z_P#SM?IQZT'A4/K_`/.U^G'K0>%0^O\`\[7ZMM!X5#Z_P#SM?IQZT'A4/K_`/.U^G'K0>%0^O\`\[7ZM!X5#Z_P#SM?IQMZT'A4/K_`/.U^G'K0>%0^O\`\[7ZM!X5#Z_P#SM?IQZT'A4/K_`/.U^G'KM0>%0^O\`\[7ZM!X5#Z_P#SM?IQZT'A4/K_`/.U^G'K0>%0^O\`\[7ZM!MX5#Z_P#SM?IQZT'A4/K_`/.U^G'K0>%0^O\`\[7ZM!X5#Z_P#SM?IQZT'AM4/K_`/.U^G'K0>%0^O\`\[7ZM!X5#Z_P#SM?IQZT'A45AZ_5?-2#L#W>O_M`*O,&_R_R&J6C0J9&$01:T(.]"#O[="#OM6];U_+K>OLWD!YP!@#`&`,`QV8?^VE*/__P#VF*OR^N7>ZDA0[5LKZ$LYMGS((PS@4^OK]8>C+7+_7U]=[VO7?4K-^N_M_Y?YI;T13NW#6.J+3DVI-*R/J5Z#8!&?6)2-CT:`.*,KE>%7GY?^=5!Q^#+FK[VZ)]FW_3$^^7E]^X]3M^N6_1'1'7Q;Q'K\@8QO>OLWH@A&K%K?\GM2''B]?_!E_!CS6][=$^S;_`*8GMWS